New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.64 2.11 +1.27%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. 10-Q filed May 7, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 5:12 PM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-K filed Feb 24, 2026: 1 added · 3 removed · 39 modified; 1 moved without change